GlycoMimetics (GLYC) to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at ASH
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
GlycoMimetics to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at 61st ASH Meeting
November 6, 2019 10:03 AM ESTLatest analysis of clinical data on novel therapeutic candidate will be shared, showing that uproleselan can augment deep clinical responses and prolong overall survival in high risk patients with acute myeloid leukemia (AML) Additional presentations highlight E-selectin as a major extrinsic contributor to chemoresistance in AML
ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that seven abstracts covering data from the companys research and clinical portfolio have been accepted for presentation at the 61st American Society of Hematology (ASH) Annual... More
